|
Huh-1
|
0.098 μM
|
MTT assay
|
Download PDF
|
|
HCCLM3
|
0.08 μM
|
MTT assay
|
Download PDF
|
|
A549 cells
|
24.13µM
|
Cell viability assay (CCK8)
|
PMC12487367
|
|
PC9 cells
|
36.38µM
|
Cell viability assay (CCK8)
|
PMC12487367
|
|
Raji cells
|
1.2 ± 0.1 μM
|
MTT assay
|
PMC11316380
|
|
Ramos cells
|
1.2 ± 0.2 μM
|
MTT assay
|
PMC11316380
|
|
RAW264.7 cells
|
1.8 ± 0.2 μM
|
MTT assay
|
PMC11316380
|
|
THP-1 cells
|
1.7 ± 0.2 μM
|
MTT assay
|
PMC11316380
|
|
SKOV3 (Parental)
|
45.94 µM
|
WST1 assay, absorbance measured using CLARIOstar, calculated by four-parameter logistic regression model
|
Download PDF
|
|
SKOV3 (MSLN+)
|
49.28 µM
|
WST1 assay, absorbance measured using CLARIOstar, calculated by four-parameter logistic regression model
|
Download PDF
|
|
OVCAR4 (Parental)
|
21.43 µM
|
WST1 assay, absorbance measured using CLARIOstar, calculated by four-parameter logistic regression model
|
Download PDF
|
|
OVCAR4 (MSLN+)
|
27.88 µM
|
WST1 assay, absorbance measured using CLARIOstar, calculated by four-parameter logistic regression model
|
Download PDF
|
|
primary CLL cells (BIRC3 mutated)
|
~2.8 µM
|
Apoptosis assessed by dual-colour immunofluorescent flow cytometry using Annexin V and propidium iodide (PI) labeling.
|
Download PDF
|
|
MA cells
|
sgCtrl: 0.4 nM; sgHerc1 #1: 0.06 nM; sgHerc1 #2: 0.12 nM
|
(CTG) assay
|
PMC11497402
|
|
CLL-CII cells
|
1.17 µM (24h), 0.70 µM (48h)
|
MTT assay, calculated by sigmoidal dose-response model using GraphPad Prism 6.01 software.
|
Download PDF
|
|
MEC1
|
29.27 µM
|
MTS cell viability assays (Aqueous One assay)
|
Download PDF
|
|
JVM2
|
9.08 µM
|
MTS cell viability assays (Aqueous One assay)
|
Download PDF
|
|
AML adult
|
1.16 μg/ml
|
MTT assay, LC50 calculated from the dose response curve
|
PMC3687416
|
|
CML adult
|
2.97 μg/ml
|
MTT assay, LC50 calculated from the dose response curve
|
PMC3687416
|
|
CML adult (non-advanced disease)
|
4.88 μg/ml
|
MTT assay, LC50 calculated from the dose response curve
|
PMC3687416
|
|
CML adult (advanced disease)
|
1.55 μg/ml
|
MTT assay, LC50 calculated from the dose response curve
|
PMC3687416
|
|
CML adult (good clinical response to imatinib)
|
3.21 μg/ml
|
MTT assay, LC50 calculated from the dose response curve
|
PMC3687416
|
|
CML adult (poor clinical response to imatinib)
|
2.67 μg/ml
|
MTT assay, LC50 calculated from the dose response curve
|
PMC3687416
|
|
CML adult (without ABL-kinase domain mutations)
|
3.21 μg/ml
|
MTT assay, LC50 calculated from the dose response curve
|
PMC3687416
|
|
CML adult (with ABL-kinase domain mutations)
|
> 20.00 μg/ml
|
MTT assay, LC50 calculated from the dose response curve
|
PMC3687416
|
|
Primary CLL cells
|
1.5 μM - 18 μM
|
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (MTT assay)
|
Download PDF
|
|
primary CLL lymphocytes
|
2.5 mM
|
colorimetric MTT assay
|
Download PDF
|
